Loading...
COYA logo

Coya Therapeutics, Inc.NasdaqCM:COYA Stock Report

Market Cap US$124.1m
Share Price
US$5.39
US$15.21
64.6% undervalued intrinsic discount
1Y-6.9%
7D11.8%
1D
Portfolio Value
​
View

Coya Therapeutics, Inc.

NasdaqCM:COYA Stock Report

Market Cap: US$124.1m

Coya Therapeutics (COYA) Stock Overview

A clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). More details

COYA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Analysts in good agreement that stock price will rise by 182.3%

Risk Analysis

Earnings are forecast to decline by an average of 9.3% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


COYA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Coya Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Coya Therapeutics
Historical stock prices
Current Share PriceUS$5.39
52 Week HighUS$7.75
52 Week LowUS$3.71
Beta0.62
1 Month Change12.06%
3 Month Change28.49%
1 Year Change-6.91%
3 Year Change22.78%
5 Year Changen/a
Change since IPO17.94%

Recent News & Updates

Recent updates

Analysis Article • Sep 16

Is Coya Therapeutics (NASDAQ:COYA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Apr 04

We Think Coya Therapeutics (NASDAQ:COYA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Oct 29

Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 13

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Summary Coya Therapeutics is developing treatments for neurodegenerative diseases, with its lead drug COYA 302 showing promising early results in ALS trials. Despite recent delays, the adverse investor reaction presents an investment opportunity as the company progresses on its pipeline development. The partnership with Dr. Reddy's Labs validates COYA 302 and provides a mechanism for rapid commercial scaling upon FDA approval. Upcoming presentations and potential new partnerships could act as catalysts for share price appreciation. Read the full article on Seeking Alpha
Analysis Article • Mar 26

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, Coya...
Seeking Alpha • Feb 13

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Summary Coya Therapeutics has strengthened its strategic positioning with a licensing deal with Dr. Reddy's, providing significant financial derisking and expanding its pipeline. The company has proven its ability to execute business development activities and is in a strong position for upcoming clinical success and potential regulatory approval. Multiple catalysts such as Alzheimer's topline data or additional business development deals could move shares higher. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Summary Coya Therapeutics is targeting inflammation in neurological diseases by modulating the function of regulatory T cells. The company has decided to put its lead asset, COYA 101, on hold due to cash problems and focus on other assets in early stage studies. Preliminary data from COYA 302 in ALS and COYA 301 in Alzheimer's disease show promising results, but the company's low cash balance poses a risk. Read the full article on Seeking Alpha
Analysis Article • Sep 06

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • May 17

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

COYAUS BiotechsUS Market
7D11.8%4.0%-2.3%
1Y-6.9%34.1%21.2%

Return vs Industry: COYA underperformed the US Biotechs industry which returned 35.2% over the past year.

Return vs Market: COYA underperformed the US Market which returned 23.3% over the past year.

Price Volatility

Is COYA's price volatile compared to industry and market?
COYA volatility
COYA Average Weekly Movement9.9%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: COYA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: COYA's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20208Arun Swaminathanwww.coyatherapeutics.com

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer’s disease (AD), and Parkinson’s disease.

Coya Therapeutics, Inc. Fundamentals Summary

How do Coya Therapeutics's earnings and revenue compare to its market cap?
COYA fundamental statistics
Market capUS$124.09m
Earnings (TTM)-US$21.13m
Revenue (TTM)US$7.94m
15.9x
P/S Ratio
-6.0x
P/E Ratio

Is COYA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
COYA income statement (TTM)
RevenueUS$7.94m
Cost of RevenueUS$15.62m
Gross Profit-US$7.68m
Other ExpensesUS$13.45m
Earnings-US$21.13m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.90
Gross Margin-96.71%
Net Profit Margin-266.11%
Debt/Equity Ratio0%

How did COYA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/23 05:19
End of Day Share Price 2026/06/23 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coya Therapeutics, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Keay NakaeChardan Capital Markets, LLC
Jason KolbertD. Boral Capital LLC.